logo
Plus   Neg
Share
Email

Genentech: Risdiplam Trial Meets Primary Goal In People With Type 2 Or 3 SMA

Genentech, a member of the Roche Group (RHHBY), announced Monday that risdiplam met primary endpoint in pivotal SUNFISH trial in people with type 2 or 3 spinal muscular atrophy or SMA.

The Part 2 of the study demonstrated statistically significant improvements in the overall study population of people aged 2-25 years with Type 2 or 3 SMA.

Risdiplam is an investigational, survival motor neuron-2 or SMN2 splicing modifier, designed to durably increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body.

The study met its primary endpoint of change from baseline in the Motor Function Measure 32 or MFM-32 scale after one year of treatment with risdiplam, compared to placebo.

According to the company, no treatment-related safety findings leading to study withdrawal have been seen in any risdiplam trial to date.

The company noted that SUNFISH is the largest placebo-controlled study ever undertaken in Type 2 or 3 SMA patients.

Levi Garraway, chief medical officer and Head of Global Product Development, stated that the positive outcome of this trial is an important milestone for people with Type 2 or 3 SMA, too many of whom remain untreated.

Data from the SUNFISH study will be presented at an upcoming medical congress.

Risdiplam is currently being evaluated in four multicenter trials in people with SMA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
WD-40 Company recalled about 130,000 units of X-14 Mildew Stain Remover for potential risk of skin irritation, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said pressure can build up inside the bottle and cause it to fall over and leak, posing a risk of skin irritation. Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020. Shares of Deutsche Lufthansa AG were losing around 3 percent in German trading after the airline reported Thursday a loss in its second quarter, compared to prior year's profit with sharply lower revenues with collapse in demand for air travel due to the Corona pandemic. Going ahead, the airline projects a clearly negative adjusted EBIT in the second half of 2020 and a further significant decline
Follow RTT